Khanmohammadi S, Masrour M, Fallahtafti P, Hasani F
Cancer Rep (Hoboken). 2025; 8(1):e70070.
PMID: 39854617
PMC: 11760998.
DOI: 10.1002/cnr2.70070.
Rashid G, Khan N, Elsori D, Youness R, Hassan H, Siwan D
Arch Gynecol Obstet. 2024; 309(5):1707-1723.
PMID: 38316651
DOI: 10.1007/s00404-024-07379-4.
Pourhamidi R, Moslemi A
J Egypt Natl Canc Inst. 2023; 35(1):19.
PMID: 37357234
DOI: 10.1186/s43046-023-00172-5.
Zhou W, Xu Y, Zhang J, Zhang P, Yao Z, Yan Z
Leukemia. 2022; 36(7):1861-1869.
PMID: 35488020
PMC: 9252898.
DOI: 10.1038/s41375-022-01565-6.
Wen H, Li F, Bukhari I, Mi Y, Guo C, Liu B
Dis Markers. 2022; 2022:7932655.
PMID: 35401882
PMC: 8986440.
DOI: 10.1155/2022/7932655.
Dysregulation of miRNAs in DLBCL: Causative Factor for Pathogenesis, Diagnosis and Prognosis.
Alsaadi M, Khan M, Dalhat M, Bahashwan S, Khan M, Albar A
Diagnostics (Basel). 2021; 11(10).
PMID: 34679437
PMC: 8535125.
DOI: 10.3390/diagnostics11101739.
Acupuncture therapy protects PCOS patients with diabetes by regulating miR-32-3p/PLA2G4A pathway.
Wu J, Chen X
Am J Transl Res. 2021; 13(8):8819-8832.
PMID: 34539997
PMC: 8430091.
Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC).
Armesto M, Marquez M, Arestin M, Errarte P, Rubio A, Manterola L
Cancers (Basel). 2021; 13(17).
PMID: 34503211
PMC: 8430814.
DOI: 10.3390/cancers13174401.
Non-Coding RNAs in Normal B-Cell Development and in Mantle Cell Lymphoma: From Molecular Mechanism to Biomarker and Therapeutic Agent Potential.
Kersy O, Salmon-Divon M, Shpilberg O, Hershkovitz-Rokah O
Int J Mol Sci. 2021; 22(17).
PMID: 34502399
PMC: 8430640.
DOI: 10.3390/ijms22179490.
Low miR-214-5p Expression Correlates With Aggressive Subtypes of Pediatric ALCL With Non-Common Histology.
Di Battista P, Lovisa F, Gaffo E, Gallingani I, Damanti C, Garbin A
Front Oncol. 2021; 11:663221.
PMID: 34113568
PMC: 8185221.
DOI: 10.3389/fonc.2021.663221.
Non-coding RNAs (miRNAs and lncRNAs) and their roles in lymphogenesis in all types of lymphomas and lymphoid malignancies.
Drillis G, Goulielmaki M, Spandidos D, Aggelaki S, Zoumpourlis V
Oncol Lett. 2021; 21(5):393.
PMID: 33777216
PMC: 7988683.
DOI: 10.3892/ol.2021.12654.
Targeting microRNA in hematologic malignancies.
Han Z, Rosen S, Querfeld C
Curr Opin Oncol. 2020; 32(5):535-544.
PMID: 32657797
PMC: 7755293.
DOI: 10.1097/CCO.0000000000000657.
MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H, Brondum R, Young K, Bogsted M, Dybkaer K
BMC Cancer. 2020; 20(1):237.
PMID: 32192453
PMC: 7082970.
DOI: 10.1186/s12885-020-6643-8.
lncRNA Colorectal Neoplasia Differentially Expressed (CRNDE) Promotes Proliferation and Inhibits Apoptosis in Non-Small Cell Lung Cancer Cells by Regulating the miR-641/CDK6 Axis.
Fan Y, Yu Z, Cui X
Med Sci Monit. 2019; 25:2745-2755.
PMID: 30982057
PMC: 6477934.
DOI: 10.12659/MSM.913420.
MicroRNAs as Biomarkers of B-cell Lymphoma.
Sole C, Arnaiz E, Lawrie C
Biomark Insights. 2018; 13:1177271918806840.
PMID: 30349178
PMC: 6195009.
DOI: 10.1177/1177271918806840.
MicroRNAs in Autoimmunity and Hematological Malignancies.
Di Marco M, Ramassone A, Pagotto S, Anastasiadou E, Veronese A, Visone R
Int J Mol Sci. 2018; 19(10).
PMID: 30322050
PMC: 6213554.
DOI: 10.3390/ijms19103139.
MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways.
Malpeli G, Barbi S, Tosadori G, Greco C, Zupo S, Pedron S
Oncotarget. 2018; 9(51):29753-29771.
PMID: 30038718
PMC: 6049865.
DOI: 10.18632/oncotarget.25707.
MicroRNA signatures and Foxp3 cell count correlate with relapse occurrence in follicular lymphoma.
Malpeli G, Barbi S, Greco C, Zupo S, Bertolaso A, Scupoli M
Oncotarget. 2018; 9(28):19961-19979.
PMID: 29731996
PMC: 5929439.
DOI: 10.18632/oncotarget.24987.
Analysis of NFKB2‑mediated regulation of mechanisms underlying the development of Hodgkin's lymphoma.
Zhang Y, Tong L, Chen S, Wu W, Wang L
Mol Med Rep. 2018; 17(6):8129-8136.
PMID: 29693141
PMC: 5983985.
DOI: 10.3892/mmr.2018.8911.
Crosstalk between microRNA and DNA Methylation Offers Potential Biomarkers and Targeted Therapies in ALK-Positive Lymphomas.
Hoareau-Aveilla C, Meggetto F
Cancers (Basel). 2017; 9(8).
PMID: 28771164
PMC: 5575603.
DOI: 10.3390/cancers9080100.
